{
 "name": "生華科",
 "slug": "tw-6492",
 "aliases": [
  "生華生物科技股份有限公司",
  "SH",
  "6492"
 ],
 "ticker": "6492",
 "industry": "生技醫療業",
 "website": "http://www.senhwabio.com",
 "summary": "生華科（6492）是上櫃的生技醫療類股公司，2012 年成立，2017 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "生華生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "SH",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2017-04-24",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2012-11-16",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "胡定吾",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "黃品諺",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 1149036200,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "http://www.senhwabio.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 80,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔數值、單位與as_of保留；2026-10-22重開官方OpenAPI逐值核對，資料年月11509、出表日期1151017，欄位：營業收入-當月營收；僅更正不符白名單的舊二手來源網址。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -51.22,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔數值、單位與as_of保留；2026-10-22重開官方OpenAPI逐值核對，資料年月11509、出表日期1151017，欄位：營業收入-去年同月增減(%)；僅更正不符白名單的舊二手來源網址。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -13.25,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔數值、單位與as_of保留；2026-10-22重開官方OpenAPI逐值核對，資料年月11509、出表日期1151017，欄位：累計營業收入-前期比較增減(%)；僅更正不符白名單的舊二手來源網址。"
  },
  {
   "claim": "管線：CX-5461（pidnarulex）",
   "value": "BRCA2及/或PALB2變異之晚期實體腫瘤｜Phase 1b擴增試驗完成收案、進入分析｜美國、加拿大",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://www.senhwabio.com/tw/news/20260825",
   "note": "官網新聞日期、正文第一段 NCT04890613（https://clinicaltrials.gov/api/v2/studies/NCT04890613）之locations佐證地區；不用較早CT.gov RECRUITING覆蓋公司完成收案公告。"
  },
  {
   "claim": "催化劑：CX-5461",
   "value": "Phase 1b擴增試驗臨床試驗報告（CSR）完成｜2027Q1（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://www.senhwabio.com/tw/news/20260825",
   "note": "官網新聞日期、正文第一段 NCT04890613；屬公司預期完成時間，非已完成。"
  },
  {
   "claim": "管線：CX-5461（pidnarulex；合併PD-1抑制劑）",
   "value": "晚期實體腫瘤｜多中心Phase 1b/2a獲FDA及TFDA核准執行｜美國、台灣",
   "unit": "",
   "as_of": "2026-08-06",
   "source": "https://www.senhwabio.com/tw/news/20260806",
   "note": "官網新聞日期及第一段 組合藥tislelizumab依同日MOPS；核准執行不等於已完成試驗。"
  },
  {
   "claim": "管線：CX-4945（silmitasertib）",
   "value": "病毒感染引發之社區型肺炎｜第二期；已終止｜台灣",
   "unit": "",
   "as_of": "2026-01-08",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06202521",
   "note": "NCT06202521；as_of取登錄最後更新發布日(lastUpdatePostDate)，僅表示該試驗登錄狀態，不代表藥品核准或整條管線現況。"
  },
  {
   "claim": "管線：CX-5461（合併cemiplimab）",
   "value": "難治型微衛星穩定型結直腸癌｜第I/II期已收治首例｜美國",
   "unit": "",
   "as_of": "2026-09-07",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6492",
   "note": "發言日期 2026-09-07 06:07:52；主旨：生華科新藥CX-5461獲美國NCI贊助聯用國際製藥大廠賽諾菲 及再生元製藥已上市免疫檢查點抑制劑Cemiplimab治療難治性微 衛星穩定型結直腸癌人體試驗已成功收治首位患者。；序號1；查詢年度115、全年度；enterDate=1150906。 NCI贊助10716研究，非與製藥廠商業授權交易。"
  },
  {
   "claim": "管線：CX-4945（silmitasertib）",
   "value": "髓母細胞瘤｜PBTC主導第I/II期因贊助到期終止｜美國",
   "unit": "",
   "as_of": "2026-03-27",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=6492",
   "note": "發言日期 2026-03-27 14:01:18；主旨：公告由於美國國家衛生研究院轄下國家癌症研究所贊助計畫 到期，本公司由美國兒童腦瘤聯盟(PBTC)主導執行之髓母細胞瘤 第1/2期人體臨床試驗終止。；序號1；查詢年度115、全年度；enterDate=1150327。 該試驗終止不代表所有CX-4945研發終止。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6492.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}